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Abstract
This cross-sectional, observational study was undertaken to
examine whether voluntary activation failure could contribute to
the persisting weakness observed in some patients with treated
idiopathic inflammatory myositis. In 20 patients with myositis of
more than six months' duration (5 males, 15 females; mean [± 1
SD] age 53 [11] years) and 102 normal subjects (44 males, 58
females; mean age 32 [8] years), isometric maximum voluntary
contractions (MVCs) of the dominant quadriceps femoris (QF)
were quantified. Absolute MVC results of normal subjects and
patients were then normalised with respect to lean body mass
(force per units of lean body mass), giving a result in Newtons
per kilogram. Based on mass-normalised force data of normal
subjects, patients were arbitrarily stratified into "weak" and "not
weak" subgroups. During further MVC attempts, the "twitch
interpolation" technique was used to assess whether the QF
voluntary activation of patients was complete. This technique
relies on the fact that, because muscle activation is incomplete
during submaximal voluntary contractions, electrical stimulation
of the muscle can induce force increments superimposed on the
submaximal voluntary force being generated. No between-
gender differences were seen in the mass-normalised MVC
results of healthy subjects, so the gender-combined results of
6.6 (1.5) N/kg were used for patient stratification. No between-
gender difference was found for mass-normalised MVCs in
patients: males 5.4 (3.2) and females 3.0 (1.7) N/kg (p > 0.05).
Mass-normalised MVCs of male patients were as great as those
of normal subjects (p > 0.05), but mass-normalised MVCs of
female patients were significantly smaller than those of the
normal subjects (p < 0.001). Only one of the six "not weak"
patients exhibited interpolated twitches during electrical
stimulation, but six of the 14 "weak" patients did, the biggest
twitches being seen in the weakest patient. That interpolated
twitches can be induced in some myositis patients with ongoing
QF weakness during supposed MVCs clearly suggests that
voluntary activation failure does contribute to QF weakness in
those patients.
Introduction
Polymyositis (PM) and dermatomyositis (DM) are the idio-
pathic inflammatory myositis subtypes most often treated by
rheumatologists [1,2]. Corticosteroids and immunosuppres-
sive drugs remain the mainstay of treatment [2], but the
response to these agents is often disappointing, so chronic
weakness and disability may persist despite treatment [3,4]. In
chronic, end-stage myositis, in which muscle wasting may be
radiologically and even clinically obvious, weakness may be
explained by loss of muscle mass which, once established,
often appears irreversible. In the early acute phase of myositis,
when muscle histology might demonstrate the characteristic
infiltration by T cells and macrophages, with secondary muscle
fibre damage and myonecrosis [5], weakness is often at its
most severe. Because early weakness usually improves with
treatment, albeit to a variable degree, it has traditionally been
assumed that muscle weakness prior to treatment results from
inflammatory processes, although the actual mechanisms
responsible for inflammatory weakness induction remain une-
lucidated. In treated myositis, recovery of strength is often
incomplete, even though radiological and histological evi-
dence suggests that inflammation has been suppressed.
BM = body mass; CK = creatinine kinase; CRP = C-reactive protein; DM = dermatomyositis; EMG = electromyography; LBM = lean body mass; 
MMT = manual muscle testing; MRI = magnetic resonance imaging; MVC = maximum voluntary contraction; PM = polymyositis; QF = quadriceps 
femorisArthritis Research & Therapy    Vol 8 No 3    Molloy et al.
Page 2 of 9
(page number not for citation purposes)
Here, especially in the absence of obvious wasting, persisting
weakness is harder to explain. Thus, it is also increasingly rec-
ognised in myositis that any correlation between the observed
weakness of a muscle and the degree of its inflammatory cell
infiltration at biopsy may be very poor [6,7]. These discussions
clearly suggest that mechanisms other than those related to
inflammation are implicated in weakness induction in myositis
[8]. Indeed, many recent studies present compelling evidence
that abnormalities of energy metabolism [9,10], possibly due
to disruption of local microcirculation [11], as well as cytokine
dysfunction [12-14], are likely involved in weakness induction.
More recently still, in murine and human myositis, activation of
the endoplasmic reticulum stress response has been demon-
strated as another, self sustaining, nonimmune mechanism
capable of inducing skeletal muscle cell dysfunction and loss
in myositis [15]. These nonimmune myositis-induced abnor-
malities would all likely cause muscle weakness by disrupting
contractile function.
Although the importance of these recent findings in terms of
understanding nonimmune-mediated weakness induction in
myositis is obvious, there are other mechanisms that may be
important and that have not been investigated to date. Skeletal
muscle weakness can result from a defect at any step in the
neuromuscular command chain governing contraction [16]. In
general, however, weakness is termed "central" if due to a
defect prior to the neuromuscular junction or "peripheral" if
due to a defect beyond the junction [16]. Applying such prin-
ciples in myositis, inflammatory damage to the muscle mem-
brane and contractile apparatus itself would obviously cause
peripheral dysfunction. Abnormalities of the spinal cord, ante-
rior horn cells, and peripheral nerves are not part of the usual
Table 1
Clinical and laboratory features of the 20 patients with idiopathic inflammatory myositis
Patient Age/
gender
IIM Subtype IIM 
duration 
(yr)
Treatment CK IU/l 
(24–170)
CRP IU/l 
(0–10)
MMT QF EMG MRI Disease 
activity
1 35/M PM/MCTD 8 P 5, Aza 60 9 5 ND ND Inactive
2 34/M DM 0.5 P 30, SELAM 95 12 5 + + Active -
3 46/M PM/CTD 6 P 20, MMF 109 40 5 ND ND Inactive
4 62/F PM 1 P 7, SELAM 97 14 5 + ND Active -
5 59/F PM 8 - 48 43 5 ND ND Inactive
6 62/F DM 6 - 129 10 4+ ND ND Inactive
7 68/F PM 1 Mtx 653 10 5 + ND Active -
8 40/F DM 6 P 30, CyA, Mtx 486 11 4+ ND ND Active -
9 47/M PM 12 P 10, Mtx 3,500 2 4- + + Active +
10 67/F PM/MCTD 10 P 10, Mtx 170 2 4+ ND + Active
11 58/F PM/UCTD 1 P 7.5, SELAM 181 2 5 ND ND Active
12 50/F PM 0.5 P 10, CyA, Aza 53 2 4 + ND Inactive
13 59/F DM 7 P 7.5, Aza 144 6 5 ND ND Active -
14 66/F PM 1 P 10, SELAM 159 2 4+ ND ND Active
15 43/F PM/MCTD 3 P 30, CyA, Aza 305 1 4 ND ND Active -
16 41/F PM 8 P 15 282 7 5 ND + Active -
17 * 49/F PM 12 P 7.5 296 22 3- ND ND Active
18 46/F PM 6 P 30, MMF 3,331 31 3+ ND ND Active +
19 * 68/F PM/MCTD 5 P 7, Mtx 83 8 4 ND ND Inactive
20 50/M DM 10 Mtx 39 2 4+ ND - Inactive
CRP and CPK levels were current at the time of recruitment and are those used during disease activity and damage assessments. Extended MMT 
score is that for dominant QF. If EMG or MRI of QF had been performed within the previous 6 months, - or + indicates the absence or presence 
of inflammation, respectively. *Patients 17 and 19 had had muscle biopsies within the previous 6 months, and both showed end-stage disease 
with severe muscle atrophy and fatty and fibrosis replacement. Aza, azathioprine; CK, creatinine kinase; CRP, C-reactive protein; CyA, cyclosporin 
A; DM, dermatomyositis; EMG, electromyography; IIM, idiopathic inflammatory myositis; IU/l, international units per litre; MCTD, mixed connective 
tissue disease; MMF, mycophenolate mofetil; MMT, manual muscle testing; MRI, magnetic resonance imaging; Mtx, methotrexate; ND, (test) not 
done; P, prednisolone (daily dose, mg); PM, polymyositis; QF, quadriceps femoris; SELAM, patient participating in "SEcond Line Agents in 
Myositis" study, so on prednisolone plus Mtx or placebo and CyA or placebo; UCTD, undifferentiated connective tissue disease.Available online http://arthritis-research.com/content/8/3/R67
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clinical spectrum of myositis, so all appear unlikely causes of
central dysfunction. However, other central factors such as
insincerity of effort due to poor motivation/perceived illness, or
pain inhibition due to myalgia, could theoretically contribute to
weakness in myositis. In addition, reflex inhibition is a possibly
relevant mechanism. It is well recognised clinically that acute
knee joint pathologies cause rapid quadriceps femoris (QF)
weakness and wasting. It has also been shown that acute
iatrogenic knee joint effusions cause QF weakness [17,18],
which can be prevented if the joint is rendered insensate by
local anaesthetic co-injected with the iatrogenic effusion [19].
It was thus concluded that acute joint knee pathologies,
including iatrogenic effusions, cause QF weakness by stimu-
lating joint afferents, which reflexively inhibit anterior horn cell
function and thereby reduce QF motor activation and cause
"arthrogenous" QF weakness [20]. In an analogous fashion, it
seems theoretically plausible in myositis that inflammatory cell
infiltrates could stimulate muscle afferents and similarly inhibit
anterior horn cell function. The result would be "myogenous"
weakness. The possibility that central activation failure from
motivational problems and/or reflex inhibition could be respon-
sible for weakness induction in myositis has never been
assessed. This study of patients with myositis was therefore
undertaken to examine the completeness of central activation
during maximum voluntary contractions (MVCs) of QF.
Materials and methods
Patients with myositis
Twenty patients (15 females and 5 males) with adult (onset at
or after 18 years) myositis, defined as definite according to the
Bohan and Peter diagnostic criteria [21], were recruited into
this observational, cross-sectional study, which was approved
by the local ethics committee. Nine patients had PM, 5 had
DM, and 6 had PM as part of a connective tissue disease over-
lap. Their mean age (± 1 SD) was 53 (11) years, and their
mean myositis disease duration was 5.6 (3.9) years (Table 1).
Current disease status of patients was assessed using the
standard clinical tools available in the outpatient setting (that
is, the results of "extended" manual muscle testing [MMT] [22]
and circulating creatinine kinase [CK] and C-reactive protein
[CRP] levels). Lower limb magnetic resonance imaging (MRI),
QF muscle biopsy by conchotome [23], and needle electromy-
ography (EMG) were not specifically used in this study to
assess disease activity, but if any of these procedures had
been undertaken for clinical reasons in the previous six
months, their results were obviously used during disease
assessments. According to the results of these clinical param-
eters, and based on "intention to treat" principles, patients'
myositis disease activity and damage status was "guesti-
mated" (Table 2). This simple scoring system was used
because, although international efforts to develop comprehen-
sive disease activity and damage assessment tools are in an
advanced state of development [24,25], work validating these
tools is still ongoing [26,27], and international consensus on
their final versions is awaited. Patients' clinical details and dis-
ease activity and damage guestimates at the time of their
recruitment are summarised in Tables 1 and 3. Patients suffer-
ing current QF myalgia were excluded because this could
have caused weakness through pain inhibition. Patients with
symptoms or signs of knee joint pathologies, such as osteoar-
thritis, that could cause arthrogenous QF weakness were also
excluded.
Normal subjects
Forty-four normal males (32.4 [7.9] years old) and 58 normal
females (28.5 [6.8] years old) were recruited from hospital
medical and nonmedical staff. Considerable efforts to age-
match these subjects with the myositis patients were made,
but older staff proved difficult to recruit; as a result, the normal
subjects were significantly younger than the patients (p  <
0.001). However, this age difference was not considered
problematic, because it was known already from MMT results
that many of the patients were weak, and the rationale for test-
ing normal subjects was not to make direct comparisons with
patients regarding QF force results. Instead, the aim of using
normal data was to set a mass-normalised QF MVC limit below
which patients' results could arbitrarily be defined as "weak"
o r  " n o t  w e a k . "  A s  w i t h  p a tients, normal subjects were
excluded if they had any symptoms or signs of knee joint
pathologies.
Measuring lean body mass, QF MVC, and mass-
normalised MVC
In patients and normal subjects, lean body mass (LBM) was
derived from skin-fold thickness measurements using well val-
idated methods [28] before MVCs of their dominant QF mus-
cle were measured on a standard isometric strain-gauge test-
chair, based on the design of Edwards and Hyde [29,30].
Because MVCs are rarely used during normal daily activities,
patients and normal subjects were first familiarised with MVC
force generation. To avoid subsequent fatigue effects on the
test day results, this was undertaken 1 week prior to formal
MVC testing. During MVC testing, subjects sat upright on the
test chair, with knees and hips set at 90 degrees. An inextensi-
ble band, velcro-fastened securely around the ankle proximal
to the malleoli, connected subjects to the force transducer.
The transducer output was amplified and simultaneously
recorded on a chart recorder, and a custom-built monitor dis-
played the attained force in Newtons. A restraining belt was
also velcro-secured around test subjects' waists during their
efforts to generate MVCs to minimise any test-induced change
in hip angle. During MVCs, subjects received vigorous verbal
encouragement to perform maximally, as well as visual feed-
back via the monitor displaying their attained force and the
chart recorder output. Contraction attempts of 3–5 seconds
were made, 1 minute apart, until MVCs were within 5% to
10% of each other, which is accepted as MVC in normal sub-
jects under these conditions [29]. With prior familiarisation
and with verbal and visual feedback, all normal subjects
attained their MVC within three attempts on the test day. TheArthritis Research & Therapy    Vol 8 No 3    Molloy et al.
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test technique and feedback given were identical for patients,
none of whom complained of QF myalgia prior to, during, or
after MVC testing.
Though a close relationship has been established between
body mass (BM) and absolute QF MVC results, the expected
force at any BM may range widely (for example, at 70 kg – the
mean [± 1 SD] QF MVC force is 350 [70] N) [29], thus making
between-subject comparisons problematic. To overcome this
problem, MVC results of normal subjects and patients were
mass-normalised. Thus, once each normal subject's and
patient's LBM had been determined, their absolute QF MVC
force was divided by their LBM, giving a mass-normalised
MVC result in Newtons per kilogram.
Twitch interpolation
Whether or not a muscle is being maximally activated voluntar-
ily can be assessed using the "twitch interpolation" technique
[31-34]. The basis of this is that, if a muscle is being submax-
imally activated voluntarily, further activation is possible by
superimposing electrical stimulation via surface electrodes
applied over the motor nerve or over the muscle motor points.
If voluntary activation is not complete, such stimulation will pro-
duce force increments over and above the submaximal volun-
tary force being generated [32] (Figure 1).
If interpolated twitches are detected during "supposed"
MVCs (as has been observed, for instance, in chronic fatigue
syndrome [35] and chronic fibromyalgia syndrome [36]
patients), this confirms that voluntary activation is not com-
plete.
It is known from previous use of the twitch interpolation tech-
nique that normal individuals, with prior familiarisation and vis-
ual feedback, can reliably attain MVCs [32,37,38], so
interpolated twitches were not deemed necessary here to
prove maximal voluntary QF activation in normal subjects. For
twitch interpolation in patients, two flexible 16 × 12 cm car-
bon-impregnated silicon equine electrodes (Henleys Medical
Supplies Ltd., Welwyn Garden City, Hertfordshire, UK) were
applied proximally and distally to the lateral and medial thigh,
respectively (that is, over the proximal and distal QF motor
points). Electrical contact was optimised with a highly conduc-
tive electromedical gel (Dracard electrode gel; Crown Graphic
Ltd., Totnes, Devon, UK). The electrode placements were
secured by a bandage wrapped around the thigh, immediately
prior to the patients' being seated on the MVC test-chair. Elec-
trical stimulation (Devices 3072; Digitimer Ltd, Welwyn Gar-
den City, Hertfordshire, UK) was computer-controlled
(Amstrad PC1640; Amstrad Plc, Brentwood, Essex, UK) by
specifically written software (Programmable Stimulator Con-
troller, PULG10 Rev 1.2; Computer Allied Services, Queens-
land, Australia) and delivered at 1 Hz. In previous interpolated
twitch studies in normal subjects, supramaximal stimulation
voltages were usually used [33,39,40], but many of our
patients with myositis appeared intolerant of such intense
stimulation, so the voltages used instead were ones that were
easily tolerated by them all. After familiarisation with twitches
at clearly submaximal voltages, all patients eventually tolerated
stimulation voltages of 90–100 V, and we were able to
increase the square-wave pulse width from 50 to 500 µs at
these voltages, which were then used during interpolation
testing.
Having determined each patient's supposed MVC, stimulated
twitches at test voltages were then delivered to the resting QF,
for further familiarisation purposes. After a 60-second rest
without stimulated twitches, these were restarted, and
patients were asked to perform QF contractions at approxi-
mately 50% of their previously attained MVC, aided by visual
feedback from their force traces, on which superimposed
twitches were then visualised. After another 60-second rest
without twitches, these were again restarted at rest and
patients were then asked to produce another 3- to 5-second
MVC, with full verbal and visual feedback, as already
described. Voluntary QF activation was deemed incomplete if,
during these supposed MVCs, interpolated twitch-induced
force increments could be seen on the voluntary force trace.
Statistical methods
The results are shown as the mean (± 1 SD). Between-group
comparisons were performed using χ2 and Mann-Whitney U
Table 2
Myositis disease activity and damage scores
Score Disease activity status (weakness attributable to activity) Score Disease damage status (weakness attributable to damage)
Inactive No disease activity. Dose decrements contemplated or 
actioned
0N o  w e a k n e s s .
Active - Mild activity, but stable. No dose increments 
contemplated, decrements contemplated or actioned.
1 Mild persisting weakness, but normal ADL and/or occupation.
Active Moderate activity. Dose increments contemplated or 
actioned.
2 Obvious persisting weakness. Limited ADL and/or occupation.
Active 
+
Severe activity. Additional agents contemplated or 
actioned.
3 Severe persisting weakness. Unable to function independently.
Patients' disease activity levels were scored on "intention-to-treat" principles. ADL, activities of daily living.Available online http://arthritis-research.com/content/8/3/R67
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tests. Pearson coefficients (r) were derived for correlation
analysis.
Results
The patients with myositis were significantly older and heavier
than the normal subjects: 53 (11) vs. 30 (8) years and 77.3
(13.2) vs. 70.5 (12.9) kg, respectively (p < 0.001 and < 0.02,
respectively). As was expected from their larger masses, nor-
mal males were significantly stronger than normal females in
absolute terms (that is, their MVCs were 388.5 (102.1) vs.
304.8 (82.5) N, p < 0.001). However, no between-gender dif-
ferences were seen for mass-normalised MVC, with MVC/
LBM results of 6.4 (1.3) and 6.8 (1.6) N/kg for normal males
and females, respectively (p > 0.05). Thus, their gender-com-
bined results of 6.6 (1.5) N/kg were used during subsequent
patient stratification (see below). With an MVC/LBM of 5.4
(3.2) N/kg, male patients were, as a group, as strong as normal
males (p > 0.05). With an MVC/LBM result of 3.0 (1.7) N/kg,
female patients were as strong as male patients (p > 0.05) but
significantly weaker than the gender-combined normals (p <
0.001).
Patients were then stratified as obviously "weak" or "not weak"
according to their mass-normalised force results. For this pur-
pose, "weak" was arbitrarily defined as a mass-normalised
MVC lower than 1 SD below the mean of the gender-com-
bined normal group (that is, below 5.1 N/kg), whereas "not
weak" was arbitrarily defined as a mass-normalised MVC
above 5.1 N/kg (Figure 2).
Of the 14 "weak" patients, 12 were female, but the individual
with the lowest mass-normalised force was in fact male. When
interpolated twitch-status was examined, seven of the 20
patients with myositis demonstrated twitches. Of the six
patients stratified as "not weak", one demonstrated twitches,
but six of the 14 patients stratified as "weak" demonstrated
twitches (Table 3). The largest interpolated twitches were
seen in the male individual with the lowest mass-normalised
force result (Figure 3).
Of the six "weak" patients displaying interpolated twitches,
five had disease designated as active, but the male subject
with the largest twitches had disease designated as inactive.
The disease duration of those "weak" patients with positive
twitches was not significantly different to that of those "weak"
patients without twitches, 7.3 (2.7) vs. 5.3 (5.5) years, respec-
tively (p  > 0.05). In two of the "weak" patients without
twitches, QF biopsies had been undertaken during the pre-
ceding 6 months to investigate whether active disease was
present and had demonstrated end-stage disease only, with
marked fibre atrophy and with fatty and fibrosis replacement.
Designated disease activity status did not influence normal-
ised strength, with mass-normalised force results of 3.1 (1.8)
vs. 4.3 (3.0) N/kg in active and inactive disease, respectively
(p > 0.05). Not surprisingly, given that patients' CK results
were used in assessing their disease activity status, there was
a significant correlation between disease activity status and
CK (r = 0.704, p < 0.01). There was, however, no correlation
between CK and CRP (r = 0.1) or between disease activity
and CRP (r = 0.13). In patients, the QF MMT results and those
of formal physiological testing by quadriceps chair correlated
poorly (for example, patients 6 and 20 both scored 4+ on
MMT), but their mass-normalised force results were very differ-
ent, whereas patients 11, 13, and 16 scored 5 on QF MMT,
but all were clearly weak on formal physiological testing.
Discussion
The detection of interpolated twitches during supposed MVCs
in nearly half of the myositis patients designated as "weak"
confirms that voluntary activation was incomplete in those sub-
jects. Moreover, given the submaximal stimulation voltages
used here, this result may represent an underestimate of the
proportion of patients with myositis who do suffer with central
activation problems. Given that current QF myalgia excluded
patient participation, to minimise the possibility of pain-related
inhibition of contraction, these results may suggest that volun-
tary activation failure had arisen through poor motivation, even
though these patients had been pushed as intensely as normal
subjects during MVC attempts, with respect to verbal encour-
agement and visual feedback, in order to maximise activation.
Alternatively, twitches would also have been detectable if
reflex inhibition of anterior horn cell function had given rise to
myogenous weakness.
One might predict that, if T cell infiltration can stimulate affer-
ents to inhibit anterior horn cell function, such inhibition would
be most marked where infiltration was greatest. This would fit
with the clinical observation that weakness is often worse
when infiltration would likely be greatest (that is, before treat-
ment starts in new-onset disease and during disease
relapses). It might therefore be speculated that interpolated
twitches would more likely be detected in acute or relapsed
disease, although this proposition has not been tested. If, how-
ever, only a small number of attacking T cells are required to
induce reflex inhibition, this could explain the poor correlation
observed between a muscle's strength deficit and the degree
of its inflammatory cell infiltration at biopsy [6,7]. This is
because, in view of their shape, muscle cells have very large
surface areas relative to the tiny fraction of which can be sam-
pled at biopsy. Small numbers of T cells could thus be present
and functionally relevant (that is, causing inhibition) yet missed
at biopsy through simple sampling error. These discussions
may, however, represent an oversimplification because,
although the largest twitches seen in this study were demon-
strated in the weakest patient, this patient's disease was clini-
cally adjudged inactive. Although the twitch interpolation
technique seems capable of detecting problems of central
activation, it cannot discern between the relative contributions
of motivational failure and reflex inhibition (that is, myogenous
weakness due to reflex inhibition remains unproven).Arthritis Research & Therapy    Vol 8 No 3    Molloy et al.
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If reflex inhibition was confirmed in myositis, what is the expla-
nation for the absence of QF twitches in some "weak" patients
with myositis? One possibility is that the inflammatory proc-
esses have been fully suppressed by treatment, so there is no
inflammatory cell infiltrate to stimulate muscle afferents. Ongo-
ing weakness in this situation would presumably then result
from the nonimmune, myositis-induced defects already dis-
cussed. Another possibility is that inflammation-induced dam-
age has disrupted the activation processes and/or the
contractile apparatus, which thus cannot respond to excita-
tion. That neuropathic EMG features occur in acute myositis
[41-43] clearly suggests that coincidental terminal motor effer-
ent, neuromuscular junction and muscle membrane damage
can occur in myositis, which would explain excitation failure-
induced weakness (that is, twitches would not be inducible if
any these defects were present). However, EMGs undertaken
in patients with more chronic myositis do not usually show
neuropathic features. Where irreversible secondary damage
to the contractile apparatus has occurred, including fibre atro-
phy and loss from fatty and/or fibrous replacement, the result-
ing contractile failure would also be insurmountable by
superimposed twitches. In keeping with these discussions,
three of the weak patients without twitches had muscle dam-
age assessed as so severe that independent living was impos-
sible, and two of these had had recent biopsies confirming the
presence of end-stage damage, with severe atrophy and fatty
and fibrous replacement. The absence of interpolated
twitches in weak patients without obvious clinical muscle
wasting is clearly in keeping with the growing body of evi-
dence demonstrating that nonimmune mechanisms are
involved in weakness induction in myositis [15] and that these
mechanisms likely cause weakness by impairing contractile
function.
If reflex inhibition does occur in myositis and it is due to affer-
ent stimulation by inflammatory cells, what is the explanation
for the detection of interpolated twitches in patients such as
the one illustrated in Figure 3 (that is, in patients whose dis-
Table 3
The muscle strength, disease activity and damage scores, and twitch interpolation results of patients with myositis
QF (MVC) Strength 
category
Patient number QF mass-normalised 
force F/LBM (N/kg)
Activity status Damage score (0–3) Twitch status (-/+)
"Not weak" 1 8.83 Inactive 0 -
27 . 1 7 A c t i v e  - 1 -
45 . 6 4 A c t i v e  - 1 -
5 5.63 Inactive 1 -
6 5.40 Inactive 1 -
3 6.40 Inactive 2 +
"Weak" 7 4.14 Active - 1 -
83 . 9 7 A c t i v e  - 1 -
93 . 6 9 A c t i v e 1 -
11 2.82 Active 1 -
12 2.28 Inactive 3 -
14 2.10 Active 1 -
*17 1.30 Active 3 -
*19 0.99 Inactive 3 -
10 3.32 Active 1 +
13 2.11 Active - 2 +
15 1.84 Active - 3 +
16 1.76 Active - 1 +
18 1.00 Active + 2 +
20 0.80 Inactive 3 +
Twenty patients with myositis listed according to their mass-normalised strength and twitch interpolation results, and stratified as "not weak" and 
"weak" according to their F/LBM results (see text). In general terms, as QF strength decreased, the incidence of positive twitches increased. 
Cases 17 and 19 had had muscle biopsies within the previous 6 months, and the results showed end-stage disease with severe muscle atrophy 
and fibrosis. F/LBM, force per units of lean body mass; MVC, maximum voluntary contraction; QF, quadriceps femoris.Available online http://arthritis-research.com/content/8/3/R67
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ease is thought inactive)? One possibility is that such disease
is not in fact inactive, but the tools used to assess disease
activity are simply too crude to detect low level disease. More
sensitive tools would clearly be required to test this possibility.
The ability to induce interpolated twitches, by surface stimula-
tion over muscle motor points, requires intact function of ter-
minal efferents, neuromuscular junctions, and muscle
membranes. Thus, the finding of interpolated twitches in some
patients seems to preclude in them the failure of any of these
structures as a cause of the voluntary weakness. A potential
alternative explanation for the finding of twitches in inactive
myositis is that irreversible damage to the afferent apparatus
(for example, muscle spindles and intrafusal fibres) occurred
before the inflammation resolved. Such "desensitization"
might reduce 1a afferent activity, thereby reducing stretch
reflex gains and the excitability of the alpha motor neurones
and so render descending motor impulses less effective. As
long as the terminal efferents, and so on, are intact, muscle
motor point stimulation would still induce interpolated
twitches. Afferent dysfunction seems an attractive explanation
here, if one considers the difficulty experienced by normal but
MVC-naïve individuals when trying to produce MVCs without
prior familiarisation/feedback. Contractions as vigorous as
MVCs are rarely used on a day-to-day basis and so are infre-
quently perceived. In normal subjects, the MVC familiarisation
process allows repeated perception of the sensation and
effort of attaining MVCs, which can thereafter be reproduced
reliably. In myositis patients with afferent damage, such famil-
iarisation would clearly be more difficult.
The sole aim of the current study was to establish whether
central activation failure occurs in patients with myositis. To
better understand the detected inability of some patients to
produce maximum force with voluntary activation and to better
understand the origin(s) of this deficit(s) will require further,
detailed neurophysiological investigations using well estab-
Figure 3
Force tracing of the male patient whose mass-normalised force was the  lowest recorded in this study Force tracing of the male patient whose mass-normalised force was the 
lowest recorded in this study. Large interpolated twitches can be seen 
on the force trace before, during, and after a supposed maximum volun-
tary contraction (MVC).
Figure 1
The effect of superimposed twitches on incremental voluntary quadri- ceps femoris (QF) contractions using the twitch interpolation technique The effect of superimposed twitches on incremental voluntary quadri-
ceps femoris (QF) contractions using the twitch interpolation tech-
nique. During a voluntary contraction, 1-Hz electrical twitches are 
delivered via surface electrodes applied over the motor nerve or muscle 
motor points. At low levels of voluntary activation (on the y-axis), a large 
proportion of muscle fibres remain unactivated, so that superimposed 
stimulation can induce large interpolated twitches. As the level of volun-
tary activation increases, the proportion of yet unactivated fibres 
decreases and so the height of the stimulation-induced interpolated 
twitches decreases until, near or at maximum voluntary contraction 
(MVC), twitches can no longer be seen (adapted from [32]).
Figure 2
Mass-normalised force results for normal subjects and the "not weak"  and "weak" patients with myositis Mass-normalised force results for normal subjects and the "not weak" 
and "weak" patients with myositis. Males and females are combined in 
all three groups. The "weak" patients with myositis were obviously 
weak relative to the other groups, with a mass-normalised force result 
of 2.2 N/kg compared with 6.6 N/kg for normal subjects and 6.5 N/kg 
for the "not weak" patients with myositis. Error bars represent + 1 SD 
from the mean. Abbreviation: F/LBM = force per units of lean body 
mass.Arthritis Research & Therapy    Vol 8 No 3    Molloy et al.
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lished techniques. These include the use of H-responses to
examine afferent function and transcranial magnetic stimula-
tion to test anterior horn cell excitability. At whatever neuro-
physiological level such investigations confirm the problem to
be, the demonstration that central factors can contribute to
weakness induction in myositis is not at odds with the other
proposed nonimmune mechanisms already outlined [8-15].
These overall discussions highlight that multifactorial contribu-
tions could be made from peripheral and central mechanisms
and could have an immune or nonimmune origin. Until more is
learnt about the mechanisms of weakness induction in myosi-
tis, designing therapies to improve strength and performance
will continue to be problematic, a situation compounded by the
limitations of the tools currently available for assessing disease
activity and damage. The disparity between the results of MMT
and formal physiological testing in patients highlights such lim-
itations.
Potential criticisms of this study include the age differences of
normal subjects and patients and the relatively small number
of patients studied. As pointed out in Materials and methods,
the rationale for having a normal group was not to make direct
comparisons with patients but instead to generate normative
mass-normalised QF MVC results from which patients could
arbitrarily be stratified as "weak" or "not weak." The normal
subject/patient age difference is also conceded, but it has not
impaired the ability to test the study hypothesis. Indeed, if only
patients' results had been presented here, proof of hypothesis
would still have been provided. The inclusion of normal sub-
jects has, however, improved our ability to discuss the poten-
tial cause(s) of the detected central activation problem. With
respect to the patient numbers used, the Salford myositis
database contains approximately 45 patients with myositis
(that is, more than many UK rheumatology units). Even so,
some of these patients are old and frail, and some were unable
or unwilling to help. Others have coexisting knee joint patholo-
gies precluding their participation, whereas others who
agreed to participate were subsequently intolerant of surface
stimulation, even at the submaximal voltages used. It is
because of the small patient numbers studied that, although
central activation failure has been demonstrated, the results
presented must be regarded as preliminary and as posing
many unanswered neurophysiological questions. Another
problem is that no attention has been paid here to the phenom-
enon of fatigue, which is very common in myositis. All central
and peripheral causes of weakness could potentially also
cause problems with fatigue, so this is a valid criticism. How-
ever, the issue of fatigue was not a study aim, so this issue will
have to be addressed in future studies.
Conclusion
This is the first study to demonstrate that voluntary activation
failure does contribute to ongoing muscle weakness in some
treated myositis patients. However, myositis-induced weak-
ness appears a multifactorial problem, comprising central acti-
vation and peripheral contractile failures and perhaps afferent
failure. Large, multicentre studies correlating clinical, neuro-
physiological, MRI, and histological parameters are now
needed to further elucidate the complex issues of weakness
induction and fatigue induction in myositis. Such studies will
need to include prospective assessments in new-onset
patients, if treatment-induced changes in the physiological var-
iables are to be assessed. Improving the treatment of myositis-
induced weakness and fatigue will depend on the outcome of
such studies.
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